Skip to main content
Erschienen in: Acta Diabetologica 4/2015

01.08.2015 | Original Article

Cord blood FGF21 in gestational diabetes and its relationship with postnatal growth

verfasst von: Ana Megia, Pilar Gil-Lluis, Silvia Näf, Victoria Ceperuelo-Mallafré, Jose Miguel Gonzalez-Clemente, Gemma Llauradó, Catalina Nuñez-Roa, Kelly Roche, Monica Ballesteros, Rosa Elena Yañez, Sonia Fernández-Veledo, Joan Vendrell

Erschienen in: Acta Diabetologica | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Background/objectives

To study whether FGF21 was present in cord blood and explore its relationship with maternal variables and postnatal growth.

Subjects and methods

The study included 157 pregnant women at the beginning of the third trimester; 79 with gestational diabetes (GDM), 78 with normal glucose tolerance (NGT), and their offspring. Glucose metabolism was assessed by oral glucose tolerance test. Insulin resistance was assessed by homeostasis model assessment index–insulin resistance (HOMA-IR). FGF21 was determined in maternal plasma drawn at recruitment and in cord blood obtained at delivery. Offspring weight and height was assessed at birth and at 12, 24 and 48 months.

Results

Maternal FGF21 was higher in gestational diabetes than in the normal glucose-tolerant group, whereas similar cord blood FGF21 levels were observed in both groups. Lower cord blood FGF21 was strongly positively correlated with maternal circulating levels. This relationship was independent of mother’s prepregnancy body mass index (BMI), glucose levels and HOMA-IR. Although maternal FGF21 levels were correlated with prepregnancy BMI and HOMA-IR index, no relationship was observed between FGF21 and birth weight. However, cord blood FGF21 levels were correlated with BMI Zeta Score at 12 and 24 months, and this relationship became stronger when only the NGT group was analyzed.

Conclusion

FGF21 is present in human cord blood, and its levels are closely correlated with maternal levels. The association observed between cord blood FGF21 and postnatal BMI may suggest a potential role during intrauterine life that may influence future metabolic imbalance.
Literatur
1.
Zurück zum Zitat Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115(6):1627–1635PubMedCentralPubMedCrossRef Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115(6):1627–1635PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochem Biophys Res Commun 1492:203–206 Nishimura T, Nakatake Y, Konishi M, Itoh N (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochem Biophys Res Commun 1492:203–206
3.
Zurück zum Zitat Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L et al (2010) Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24(10):2050–2064PubMedCentralPubMedCrossRef Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L et al (2010) Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 24(10):2050–2064PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5(6):415–425PubMedCrossRef Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V et al (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5(6):415–425PubMedCrossRef
5.
Zurück zum Zitat Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5(6):426–437PubMedCrossRef Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5(6):426–437PubMedCrossRef
6.
Zurück zum Zitat Lundäsen T, Hunt MC, Nilsson L-M, Sanyal S, Angelin B, Alexson SEH et al (2007) PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360(2):437–440PubMedCrossRef Lundäsen T, Hunt MC, Nilsson L-M, Sanyal S, Angelin B, Alexson SEH et al (2007) PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360(2):437–440PubMedCrossRef
7.
Zurück zum Zitat Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M (2008) FGF21 attenuates lipolysis in human adipocytes—a possible link to improved insulin sensitivity. FEBS Lett 582(12):1725–1730PubMedCrossRef Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M (2008) FGF21 attenuates lipolysis in human adipocytes—a possible link to improved insulin sensitivity. FEBS Lett 582(12):1725–1730PubMedCrossRef
8.
Zurück zum Zitat Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE et al (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55(9):2470–2478PubMedCrossRef Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE et al (2006) Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 55(9):2470–2478PubMedCrossRef
9.
Zurück zum Zitat Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149(12):6018–6027PubMedCrossRef Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y et al (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149(12):6018–6027PubMedCrossRef
10.
Zurück zum Zitat Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(January):250–259PubMedCentralPubMedCrossRef Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G et al (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(January):250–259PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou Z, Liu F et al (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(May):1246–1253PubMedCrossRef Zhang X, Yeung DCY, Karpisek M, Stejskal D, Zhou Z, Liu F et al (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(May):1246–1253PubMedCrossRef
12.
Zurück zum Zitat Chavez A, Molina-Carrion M, Abdul-Ghani M, Folli F, DeFronzo R, Tripathy D (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32:1542–1546PubMedCentralPubMedCrossRef Chavez A, Molina-Carrion M, Abdul-Ghani M, Folli F, DeFronzo R, Tripathy D (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32:1542–1546PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Chen C, Cheung B, Wang Y, Law L, Leung K, Wat N et al (2011) High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes. Diabetes Care 34:11–13 Chen C, Cheung B, Wang Y, Law L, Leung K, Wat N et al (2011) High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes. Diabetes Care 34:11–13
14.
Zurück zum Zitat Catalano PM, Hauguel-De Mouzon S (2011) Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? Am J Obstet Gynecol 204(6):479–487PubMedCentralPubMedCrossRef Catalano PM, Hauguel-De Mouzon S (2011) Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? Am J Obstet Gynecol 204(6):479–487PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Nitert MD, Barrett HL, Kubala MH, Scholz Romero K, Denny KJ, Woodruff TM et al (2014) Increased placental expression of fibroblast growth factor 21 in gestational diabetes mellitus. J Clin Endocrinol Metab 99(4):E591CrossRef Nitert MD, Barrett HL, Kubala MH, Scholz Romero K, Denny KJ, Woodruff TM et al (2014) Increased placental expression of fibroblast growth factor 21 in gestational diabetes mellitus. J Clin Endocrinol Metab 99(4):E591CrossRef
16.
Zurück zum Zitat Tan BK, Sivakumar K, Bari MF, Vatish M, Randeva HS (2013) Lower cerebrospinal fluid/plasma fibroblast growth factor 21 (FGF21) ratios and placental FGF21 production in gestational diabetes. PLoS One 8(6):e65254PubMedCentralPubMedCrossRef Tan BK, Sivakumar K, Bari MF, Vatish M, Randeva HS (2013) Lower cerebrospinal fluid/plasma fibroblast growth factor 21 (FGF21) ratios and placental FGF21 production in gestational diabetes. PLoS One 8(6):e65254PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Wang D, Zhu W, Li J, An C, Wang Z (2013) Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history. PLoS One 8(11):e81190PubMedCentralPubMedCrossRef Wang D, Zhu W, Li J, An C, Wang Z (2013) Serum concentrations of fibroblast growth factors 19 and 21 in women with gestational diabetes mellitus: association with insulin resistance, adiponectin, and polycystic ovary syndrome history. PLoS One 8(11):e81190PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren H-J, Drynda K et al (2010) Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 59(1):33–37PubMedCrossRef Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren H-J, Drynda K et al (2010) Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism 59(1):33–37PubMedCrossRef
19.
Zurück zum Zitat GEDE. Grupo Español de Diabetes y Embarazo (2006) Guía asistencial de diabetes mellitus y embarazo (3a edición). Av en Diabetol 22:73–87 GEDE. Grupo Español de Diabetes y Embarazo (2006) Guía asistencial de diabetes mellitus y embarazo (3a edición). Av en Diabetol 22:73–87
20.
Zurück zum Zitat National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057CrossRef National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039–1057CrossRef
22.
Zurück zum Zitat Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
23.
Zurück zum Zitat Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y (2012) Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7(3):e33870PubMedCentralPubMedCrossRef Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y (2012) Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS One 7(3):e33870PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M et al (2008) BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22(4):1006–1014PubMedCrossRef Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M et al (2008) BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22(4):1006–1014PubMedCrossRef
25.
Zurück zum Zitat Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F et al (2011) Hepatic FGF21 expression is induced at birth via PPARα in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab 11(3):206–212CrossRef Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F et al (2011) Hepatic FGF21 expression is induced at birth via PPARα in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab 11(3):206–212CrossRef
26.
Zurück zum Zitat Hondares E, Gallego-Escuredo JM, Flachs P, Frontini A, Cereijo R, Goday A et al (2014) Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue. Metabolism 63(3):312–317PubMedCrossRef Hondares E, Gallego-Escuredo JM, Flachs P, Frontini A, Cereijo R, Goday A et al (2014) Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue. Metabolism 63(3):312–317PubMedCrossRef
27.
Zurück zum Zitat Xu L, Ping F, Yin J, Xiao X, Xiang H, Ballantyne CM et al (2013) Elevated plasma sparc levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS One 8(12):e81615PubMedCentralPubMedCrossRef Xu L, Ping F, Yin J, Xiao X, Xiang H, Ballantyne CM et al (2013) Elevated plasma sparc levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS One 8(12):e81615PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Stepan H, Kley K, Hindricks J, Kralisch S, Jank A, Schaarschmidt W et al (2013) Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia. Cytokine 62(2):322–326PubMedCrossRef Stepan H, Kley K, Hindricks J, Kralisch S, Jank A, Schaarschmidt W et al (2013) Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia. Cytokine 62(2):322–326PubMedCrossRef
29.
Zurück zum Zitat Noctor E, Crowe C, Carmody LA, Kirwan B, O’Dea A, Glynn LG, et al (2014) ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by international association of diabetes in pregnancy study groups criteria. Acta Diabetol. doi:10.1007/s00592-014-0621-z Noctor E, Crowe C, Carmody LA, Kirwan B, O’Dea A, Glynn LG, et al (2014) ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by international association of diabetes in pregnancy study groups criteria. Acta Diabetol. doi:10.​1007/​s00592-014-0621-z
30.
Zurück zum Zitat Reinehr T, Woelfle J, Wunsch R, Roth CL (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 97(6):2143–2150PubMedCrossRef Reinehr T, Woelfle J, Wunsch R, Roth CL (2012) Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 97(6):2143–2150PubMedCrossRef
31.
Zurück zum Zitat Savona-Ventura C, Vassallo J, Marre M, Karamanos BG (2012) Hyperglycaemia in pregnancy in Mediterranean women. Acta Diabetol 49(6):473–480PubMedCrossRef Savona-Ventura C, Vassallo J, Marre M, Karamanos BG (2012) Hyperglycaemia in pregnancy in Mediterranean women. Acta Diabetol 49(6):473–480PubMedCrossRef
32.
Zurück zum Zitat Ignell C, Shaat N, Ekelund M, Berntorp K (2013) The impact of ethnicity on glucose homeostasis after gestational diabetes mellitus. Acta Diabetol 50(6):927–934PubMedCrossRef Ignell C, Shaat N, Ekelund M, Berntorp K (2013) The impact of ethnicity on glucose homeostasis after gestational diabetes mellitus. Acta Diabetol 50(6):927–934PubMedCrossRef
33.
Zurück zum Zitat Sletner L, Nakstad B, Yajnik CS, Mørkrid K, Vangen S, Vårdal MH et al (2013) Ethnic differences in neonatal body composition in a multi-ethnic population and the impact of parental factors: a population-based cohort study. PLoS One. 8(8):e73058PubMedCentralPubMedCrossRef Sletner L, Nakstad B, Yajnik CS, Mørkrid K, Vangen S, Vårdal MH et al (2013) Ethnic differences in neonatal body composition in a multi-ethnic population and the impact of parental factors: a population-based cohort study. PLoS One. 8(8):e73058PubMedCentralPubMedCrossRef
Metadaten
Titel
Cord blood FGF21 in gestational diabetes and its relationship with postnatal growth
verfasst von
Ana Megia
Pilar Gil-Lluis
Silvia Näf
Victoria Ceperuelo-Mallafré
Jose Miguel Gonzalez-Clemente
Gemma Llauradó
Catalina Nuñez-Roa
Kelly Roche
Monica Ballesteros
Rosa Elena Yañez
Sonia Fernández-Veledo
Joan Vendrell
Publikationsdatum
01.08.2015
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 4/2015
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0705-9

Weitere Artikel der Ausgabe 4/2015

Acta Diabetologica 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.